85,500 Shares in Guardant Health, Inc. $GH Purchased by Atika Capital Management LLC

Key Points

• Atika Capital Management LLC invested approximately $3.64 million in Guardant Health, acquiring 85,500 shares and holding about 0.07% of the company's stock.
• Guardant Health reported a quarterly revenue of **$232.09 million**, exceeding analyst expectations and showing a 31% increase year-over-year.
• Brokerages have raised their price targets for Guardant Health, with **TD Securities** and **Piper Sandler** both increasing their targets to **$60**, indicating a bullish outlook on the stock.

Atika Capital Management LLC purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 85,500 shares of the company's stock, valued at approximately $3,642,000. Atika Capital Management LLC owned about 0.07% of Guardant Health as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of the company. NewEdge Advisors LLC raised its holdings in shares of Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after buying an additional 230 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Guardant Health by 0.3% in the first quarter. American Century Companies Inc. now owns 104,206 shares of the company's stock worth $4,439,000 after buying an additional 282 shares during the last quarter. HighTower Advisors LLC increased its holdings in Guardant Health by 0.9% in the 1st quarter. HighTower Advisors LLC now owns 51,107 shares of the company's stock worth $2,177,000 after buying an additional 469 shares during the period. PNC Financial Services Group Inc. increased its holdings in Guardant Health by 25.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company's stock worth $112,000 after buying an additional 537 shares during the period. Finally, GF Fund Management CO. LTD. increased its holdings in Guardant Health by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,164 shares of the company's stock worth $135,000 after buying an additional 570 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Guardant Health

In related news, Director Ian T. Clark sold 6,672 shares of Guardant Health stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $48.38, for a total value of $322,791.36. Following the sale, the director owned 9,851 shares of the company's stock, valued at approximately $476,591.38. This trade represents a 40.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Myrtle S. Potter sold 2,626 shares of Guardant Health stock in a transaction on Monday, June 16th. The shares were sold at an average price of $49.70, for a total transaction of $130,512.20. Following the completion of the sale, the director directly owned 18,180 shares in the company, valued at $903,546. This represents a 12.62% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 235,542 shares of company stock worth $11,852,491 in the last ninety days. Company insiders own 6.10% of the company's stock.

Guardant Health Price Performance

GH stock traded up $0.48 during midday trading on Monday, hitting $61.88. 1,519,861 shares of the stock traded hands, compared to its average volume of 2,388,129. The firm has a market cap of $7.72 billion, a P/E ratio of -18.47 and a beta of 1.43. The stock's fifty day simple moving average is $50.26 and its 200-day simple moving average is $45.96. Guardant Health, Inc. has a 1-year low of $20.14 and a 1-year high of $62.81.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.08. The company had revenue of $232.09 million during the quarter, compared to analyst estimates of $211.19 million. During the same period in the prior year, the business posted ($0.84) EPS. Guardant Health's revenue was up 31.0% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. On average, research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analysts Set New Price Targets

GH has been the topic of several research reports. TD Securities increased their price target on shares of Guardant Health from $56.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Scotiabank increased their price target on shares of Guardant Health from $57.00 to $60.00 and gave the stock a "sector outperform" rating in a report on Thursday, July 31st. UBS Group increased their price target on shares of Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Piper Sandler reiterated an "overweight" rating and issued a $60.00 price target (up previously from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. Finally, Mizuho increased their price target on shares of Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Friday, June 13th. One investment analyst has rated the stock with a Strong Buy rating and sixteen have issued a Buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $57.50.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.